Toll-like receptors (TLRs) are pattern recognition receptors important for the detection of pathogen-associated molecular patterns. They are localized on cellular membranes, on either the cell surface or the endosomes. Primary Sj€ ogren's syndrome (pSS) is a systemic rheumatic autoimmune disease characterized by lymphocytic infiltrations in exocrine glands resulting in dryness in eyes and mouth. In a majority of patients, autoantibodies against Ro/SSA and/or La/SSB are present. Here we analysed mRNA levels of TLR1-10 and protein expression levels of most of them in human peripheral blood mononuclear cells from 20 patients with pSS and 20 healthy controls. Patients with pSS showed significantly higher mRNA levels of TLR8 than controls, while transcript levels of TLR9 were significantly lower. At the protein level, patients with pSS expressed significantly less TLR5 and significantly more TLR7 compared with healthy controls. TLR7 and 8 are encoded by genes localized on the X chromosome, which is especially interesting regarding the gender imbalance of pSS. The differential expression of various TLR in PBMC of patients with pSS might contribute to an altered recognition of nucleic acids, eventually resulting in the development of autoimmune disease.
Introduction
Sj€ ogren's syndrome (SS) is a chronic, rheumatic autoimmune disease, characterized by lymphocytic infiltration, destruction and dysfunction of exocrine glands. The main symptoms are ocular and oral dryness, as well as joint pain and fatigue. Many patients have systemic manifestations in addition to the main symptoms. Mainly middle-aged woman are affected as the female-to-male ratio is 9:1, and the average age of diagnosis is late 40s [1] [2] [3] [4] .
Toll-like receptors (TLRs) are a family of transmembrane proteins involved in the first line of defence against infections. As pattern recognition receptors (PRRs), they recognize a variety of pathogen-associated molecular patterns (PAMPs) [5] . There are 10 different TLRs in humans, identifying different PAMPs. TLR1, 2, 4, 5, 6 and 10 are found in the cell membrane, while TLR3, 7, 8 and 9 are localized in the endosomal compartment. Endosomal TLRs recognize nucleic acids from pathogens or from the host. TLR3 is activated by dsRNA [6] , TLR7 and 8 recognize ssRNA [7, 8] , while TLR9 is activated by unmethylated CpG DNA [9] . The TLRs found on the cell surface recognize bacterial components, TLR1, 2 and 6 detect peptidoglycan and lipoproteins, TLR4 binds LPS, and TLR5 recognizes bacterial flagella, while the ligand for TLR10 is still unknown [10] .
Toll-like receptors are supposed to protect us from invading pathogens. In addition, they can recognize endogenous molecules expressed on damaged cells (damage-associated molecular patterns; DAMPs) in line with Polly Matzinger's 'danger' hypothesis [11] . However, when not properly regulated, some of the TLRs may recognize nucleic acids from the host, resulting in autoimmunity. The endosomal TLRs, especially TLR7 and 9, are the ones involved in recognition of self-nucleic acids, and may be responsible for initiating responses leading to autoimmunity [12] . These nucleic acids are released during cell death, and necrosis is known to generate more self-stimulatory ligands compared with apoptosis [12] . The intracellular localization of these receptors was found to be important to reduce recognition of self-DNA and necessary to detect viral-RNA [13] .
Few studies on TLR expression in pSS have been published so far. Upregulated levels of TLR7 and 9 mRNA in PBMC from patients with pSS have been reported previously [14] , while our recent analyses of TLR7 and 9 revealed similar expression levels in B cells between patients with pSS and healthy controls at both mRNA and protein levels [15] . In addition to these studies on PBMC and B cells, TLR2, 3 and 4 mRNA expression in salivary gland epithelial cell (SGEC) lines derived from patients with SS were found to be significantly higher compared with control SGEC lines [16] . It was also shown that TLR2 ligation induced production of IL-23/IL-17 via IL-6, STAT3 and NF-jB pathway in pSS [17] .
Immunohistochemical analyses of TLR2, 3 and 4 performed on labial salivary gland tissue from twelve patients with pSS and four controls showed stronger expression levels in patients with pSS compared with controls [18] . The purpose of the present study was to investigate expression levels of TLR1-10 in PBMC of patients with pSS compared with age-and gender-matched controls by qPCR and Western blot.
Materials and methods
Patient samples. PBMC from 20 patients with pSS fulfilling the American European consensus group criteria (AECC) were analysed in this study ( Table 1 ). All patients were from the Department of Rheumatology, Haukeland University Hospital in Bergen, Norway. The study was approved by the Regional Committee for Research Ethics (#242.06), and all studied subjects gave their informed consent. Twenty age-matched healthy control samples from the same geographical area were collected from the Blood bank, Department of Immunology and Transfusion Medicine, also at Haukeland University Hospital. PBMC were isolated by density gradient centrifugation as described previously [19] . In short, the heparinized blood was layered on top of Lymphoprep and centrifuged at 800 g for 23 min. The PBMC were recovered from the interphase, washed three times with cold PBS and frozen down in AB plasma + 10% DMSO at À150°C, at approximately 5 9 10 6 cells per ml. Preparation of RNA, cDNA synthesis and qPCR. Total RNA from approximately 5 9 10 6 cells was isolated using RNeasy Plus mini kit (QIAGEN, Hilden, Germany) following the manufacturer's protocol. RNA concentration was measured by nanodrop, and cDNA synthesis was performed from 70 ng RNA in a 20-ll cDNA reaction using RevertAid H Minus Reverse Transcriptase (Fermentas, St. Leon-Rot, Germany). For each sample, two reactions were performed, one using Oligo (dT) 18 primer and one using random nonamer primer. cDNA from both reactions were then pooled and diluted 1:2.5, and 5 ll was used in a 20 ll real-time quantitative reverse transcriptase polymerase chain reaction using TaqMan technology. The same amount of cDNA was used to analyse all TLR (TLR1-10) and GAPDH in duplicate (TLR1, Hs00413978; TLR2, Hs00610101; TLR3, Hs00152933; TLR4, Hs00152939; TLR5, Hs00152825; TLR6, Hs01039989; TLR7, Hs00152971; TLR8, Hs00152972; TLR9, Hs00152973; TLR10, Hs00374069) and GAPDH (Hs02758991), all from Applied Biosystems, Carlsbad, CA, USA. Signals were detected using an ABI 7500 RealTime PCR System (Applied Biosystems).
Protein lysates and Western blot analyses. Whole-cell lysates using freshly prepared RIPA buffer (50 mM Tris pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM EDTA; 19 protease inhibitor (Roche, Mannheim, Germany); 1 mM PMSF; 1 mM sodium orthovanadate; 1 mM sodium fluoride) were prepared from approximately 5 9 10 6 cells as described previously [20] . In short, 100 ll RIPA buffer was added per 1 9 10 6 cells and incubated on ice for 10 min. After 5 min of centrifugation at >16,000 g and 4°C, the lysate was transferred to a new tube and stored at -80°C until further use. About 20 lg protein per lane was loaded on SDS-polyacrylamide gels (8%), and proteins were transferred to nitrocellulose membranes. Blocking of unspecific binding was performed for 1 h using 5% BSA in TBST (0.1%). The following antibodies were used: TLR2 (EPNCIR133), TLR5 (EPR10373), TLR7 (EPR2088 (2)) (all from Abcam, Cambridge, UK), TLR4 (SC-293072) (Santa Cruz, Dallas, TX, USA), TLR6 (10333) (NovusBio, Littleton, CO, USA), TLR8 (D3Z6J), TLR9 (D2C9) and MyD88 (D80F5) (all from Cell Signaling Technology, Danvers, MA, USA). All primary antibodies were diluted in 5% BSA in TBST (0.1%) and incubated overnight at 4°C with agitation. TLR4, 5 and 7 were diluted 1:500, and MyD88, TLR2, 6, 8 and 9 were diluted 1:1000. GAPDH (5G4; HyTest, Laboratories) . By calculating the density of the bands relative to a standard sample used on all blots set to 100%, and using GAPDH as loading control, expression levels were calculated. Statistical analyses. Statistical significance was evaluated using PRISM (GraphPad Software Inc., La Jolla, CA, USA), and Mann-Whitney U-test was used to analyse differences between patients with pSS and healthy controls. We did not adjust for multiple comparisons.
Results
Analysis of TLR1-10 mRNA levels revealed that patients with pSS showed significantly higher mRNA levels of TLR8 than controls, while transcript levels of TLR9 were lower in patients with pSS than in controls. Transcript levels of TLR1, 2, 3, 4, 5, 6, 7 and 10 were similar in patients with pSS and controls. In general, patients with pSS showed a higher variability in transcript levels than the healthy controls (Fig. 1) . The highest transcript levels were seen for TLR2, while TLR3 was almost undetectable. Also mRNA levels for TLR8 and TLR9 were very low in both, patients with pSS and controls.
In addition to mRNA levels, protein levels of TLR 2, 4, 5, 6, 7, 8 and 9 were analysed by Western blotting. PBMC of patients with pSS expressed significantly less TLR5 and significantly more TLR7 (Fig. 2) while the other TLRs were expressed at similar levels. Expression of TLR2 was highest also at protein level, while most of the other TLRs analysed were expressed at very low levels resulting in a very weak signal despite using an ultrasensitive substrate enabling detection of proteins in the range of a few femtograms. The variability in TLR protein levels was similar in both, patients with pSS and controls. Moreover, we analysed expression levels of adaptor protein MyD88 which is used by most of the TLRs (Fig. 3) . However, no obvious differences between patients with pSS and controls were detected.
Discussion
In this study, we analysed expression of all 10 TLRs in PBMC and compared patients with pSS with healthy controls. PBMC of patients with pSS expressed more TLR8 and less TLR9 at mRNA level than the healthy controls, and more TLR7 and less TLR5 at protein level. Interestingly, both TLR7 and 8 are encoded by genes localized on the X chromosome. This is especially intriguing as more than 90% of patients with pSS are females [21] . Remarkably, neither the upregulation of TLR8 nor the downregulation of TLR9 could be confirmed at the protein level. It should be noted, however, that our results were not corrected for multiple comparisons. Our result regarding mRNA levels differs from a study by Zheng and coworkers who analysed mRNA levels of TLR7, 8 and 9 in PBMC of patients with pSS [14] . They analysed mRNA level only and found higher expression of TLR7 and TLR9 and similar expression of TLR8 comparing patients with pSS and controls. We did detect increased protein levels of TLR7 in patients with pSS, but not mRNA levels. However, the two studies are quite different and difficult to compare. We used gender-and age-matched healthy blood donors as control group in our study, while the Asian study used patients with either oral dryness or chronic parotitis, but without detection of autoantibodies or positive focus score in biopsies. Moreover, all individuals included in our study were Caucasians, while their patients were Asian. Differences in clinical characteristics have been found between Asian and European cohorts [22] , and our patient data confirm that the Asian patient cohort is approximately a decade younger than our patients. Moreover, we used TaqMan technology to quantify TLR mRNA levels, while the Asian study lacks information as to which technology was used. The primer sequences given suggest that a more general fluorescent DNA intercalating dye such as SYBR Green was used.
We intended to analyse both mRNA and protein levels of all TLRs. Unfortunately, we were not able to analyse protein levels of TLR1, 3 and 10 due to problems with these antibodies. We unsuccessfully tested several different commercially available antibodies for each of these TLRs (at least two), but were unable to define the specific corresponding protein band on the Western blots. When we compare our results at mRNA and protein levels, most of the results correspond, although our analyses at the protein level showed lower TLR5 level in patients with pSS compared with controls (Fig. 2) , while mRNA data indicate a slightly higher level in patients with pSS ( Fig. 1, not significant) . Comparing mRNA and protein levels might not necessarily reveal the same result, as not all RNA transcripts will be translated into proteins. One study correlating RNA level and protein profile in more than 1000 genes in 23 different human cell lines found significant correlation in only 33% of the products [23] .
Expression levels of various TLRs have been analysed in other autoimmune diseases. In SLE, expression of TLRs has been carefully studied the last decade, and both protein and mRNA levels of TLR expression in PBMC and other cell Figure 1 Increased expression of TLR8 and decreased expression of TLR9 mRNA in PBMC from patients with pSS. RNA was isolated from approximately 5 9 10 6 PBMC from 20 patients with pSS and 20 healthy controls. cDNA was generated and mRNA expression was analysed for TLR1-10 and GAPDH in duplicate by TaqMan technology. Relative amount of TLR1-10 mRNA was normalized to GAPDH, and median is presented in the figures.
Ó 2016 The Foundation for the Scandinavian Journal of Immunology subsets have been analysed. Studies on PBMC mRNA showed upregulated TLR2, 7 and 9, and African American patients showed significantly higher TLR9 levels compared with European American patients [24, 25] . Analyses on protein level performed by flow cytometry often describe TLR expression on cell subsets in addition to PBMC, and published data show upregulated levels of TLR3 and 9 in PBMC and CD3+ T cells, and TLR3, 7 and 9 in CD19+ B cells [26] . Another study found less TLR2 and similar amount of TLR4 on CD14+ monocytes from patients with SLE, and more TLR9 in CD19+ B cells [27] . A third study on protein level found upregulated levels of TLR1, 2, 3, 4, 5, 6, 8 and 9 on CD4+ and CD8+ T cells, and upregulated TLR2, 3, 4, 5, 6, 8 and 9 in CD14+ monocytes and CD19+ B cells [28] . There are some diverging results between these studies; however, the consistent findings are increased TLR7 and TLR9 in patients with SLE, especially in B cells and monocytes. So far, TLRs have been given a more important role in SLE than in pSS, as more studies have been conducted, and more differences between patients and controls have been found.
Treatments of autoimmune diseases by modulating TLR signalling are under investigation. If one or more TLRs are found overexpressed or activated in a disease, then it might be possible to inhibit signalling to reduce disease activity. Plaquenil (hydroxychloroquine) is one of the most common drugs given to patients with pSS. It blocks endosomal TLR signalling, by changing the pH in endosomes, resulting in dissociation of TLR receptors and ligands [29] . However, recently the effect of plaquenil on pSS has been questioned as a patient group medicated with plaquenil did not improve symptoms when compared to a placebo group during 24 weeks of treatment [16] . Parameters assessed in the study were dryness, pain and fatigue, and the primary endpoint after 24 weeks treatment was number of patients with a reduction in score of 30% or greater in two of three parameters. At 24 weeks, 17.9% in the plaquenil group and 17.2% in the placebo group met the primary endpoint [30] .
One possible explanation for the observed differential expression of TLRs in PBMC might be differences in the general cellular composition of PBMCs in patients with pSS compared with controls. Several cell populations have been reported to be reduced in patients with pSS, for example plasmacytoid dendritic cells [31, 32] , lymphocytes (especially CD4+ T cells) [32, 33] and NK cells [34] .
The differential expression of various TLRs in PBMC of patients with pSS might contribute to an altered recognition of nucleic acids, eventually resulting in the development of autoimmune disease. Future studies using patients with pSS will have to differentiate between different cell types, and it is hoped that further studies on TLRs in pSS will give more answers if TLRs are differentially expressed in patients, thereby being potential targets for therapy.
